Payer Policy

Humana Prior Authorization Guide 2026: MCPs, Timelines & Appeal Strategy

Humana prior authorization requirements for 2026: Medical Coverage Policy numbers, Medicare Advantage timelines, step therapy criteria, peer-to-peer contacts, and how to appeal Humana denials.

RxCheckUp Clinical Team · 2026-04-17 · 13 min read

Humana Prior Authorization Overview

Humana is the second-largest Medicare Advantage insurer in the United States, covering more than 5 million MA members, and also administers commercial employer plans, Medicaid managed care, and TRICARE. Each line of business has distinct prior authorization requirements, submission channels, and decision timelines — a Humana commercial PA and a Humana Medicare Advantage PA follow different rules even though both carry the Humana name.

Humana's clinical coverage policies are published as Medical Coverage Policies (MCPs). Each MCP covers a specific drug, device, or procedure and sets out the medical necessity criteria, step therapy requirements, required documentation, and quantity/duration limits that Humana applies when reviewing a PA request. MCPs are publicly available at humana.com under Provider Resources → Coverage Policies. Citing the correct MCP number in the PA submission is one of the highest-leverage steps a practice can take to improve first-pass approval rates — it signals to the reviewer that the submission is already mapped to the applicable policy.

Humana Medical Coverage Policies: How to Find and Use Them

Humana's MCP library is organized by drug name, procedure type, and policy number. The search function at humana.com allows lookup by drug name, NDC, J-code, or MCP number. Each MCP is date-stamped and versioned — Humana updates MCPs quarterly, typically following FDA approvals and major guideline updates. Always verify you are referencing the version in effect on the date of the PA submission, as criteria can change mid-year.

MCP structure follows a standard format: (1) Indications — what Humana will and will not cover; (2) Criteria — the specific conditions a patient must meet; (3) Documentation — what must be submitted with the request; (4) Limitations — quantity limits, duration caps, site-of-care requirements. Denials cite the specific criterion not met. A strong PA submission pre-addresses each criterion with attached documentation, and a strong appeal quotes the MCP criterion and provides the clinical evidence that demonstrates compliance.

Submission Channels by Line of Business

Humana accepts PA submissions through several channels depending on the type of benefit and line of business. Using the wrong channel is a common source of administrative delays and misdirected faxes.

✓ Medical benefit PA (commercial and MA): Availity portal at availity.com → Humana payer → Authorizations; or Humana provider portal at provider.humana.com; fax to 1-888-447-3430 for commercial, 1-800-523-0023 for MA
✓ Part D pharmacy benefit PA: electronic PA through CoverMyMeds, Surescripts RTBT, or the dispensing specialty pharmacy; fax to 1-877-486-2621 for Part D
✓ Medicare Advantage home infusion: Humana Pharmacy Solutions handles home infusion PA separately from medical benefit — contact 1-800-379-0092
✓ TRICARE: Humana Military administers TRICARE East; PA for TRICARE submits through the Humana Military provider portal
✓ Electronic PA: most major EHRs support ePA submission to Humana through Availity and Surescripts; ePA decisions average significantly faster than fax for routine drug requests
✓ Always confirm the benefit channel (medical vs. Part D pharmacy) before submitting — a drug available as both a self-injected specialty product (pharmacy benefit) and an IV infusion (medical benefit) has different PA pathways and different MCP criteria

Humana Medicare Advantage Prior Authorization Timelines

Humana MA plans must comply with CMS-mandated decision timelines. These timelines are non-negotiable — if Humana misses them, the PA is deemed approved by operation of federal regulation (42 CFR 422.568).

✓ Standard pre-service medical PA: 14 calendar days from receipt of request
✓ Expedited pre-service medical PA: 72 hours (request expedited review when delay would seriously jeopardize health or function)
✓ Standard Part D coverage determination: 72 hours
✓ Expedited Part D coverage determination: 24 hours
✓ Post-service claims: 60 calendar days
✓ Humana MA appeal Level 1 (Organization Determination): 60 days to file; 30 days to respond (standard), 72 hours (expedited)
✓ If Humana misses the decision deadline, contact the MA member services line and cite 42 CFR 422.568 — the plan must issue a notice of the missed deadline and the request is constructively denied, opening the appeal window

Humana Commercial PA Timelines

For fully insured commercial plans, Humana must comply with state insurance law timelines, which vary by state. For self-insured ERISA employer plans, federal ERISA timelines apply: 15 days for standard pre-service decisions, 72 hours for urgent pre-service, 30 days for post-service. Most Humana commercial plan PA decisions are issued within 3-5 business days for routine drug requests submitted with complete documentation.

Step Therapy Requirements by Drug Class

Humana's step therapy requirements are specified in each MCP and are among the most consistently documented of any major payer. Key drug classes with step therapy requirements:

✓ TNF inhibitors (Humira biosimilars, Enbrel, Remicade/infliximab biosimilars): MCP requires documented failure of at least one conventional DMARD (methotrexate, leflunomide, sulfasalazine) at therapeutic dose for ≥3 months for RA indications; IBD indications require corticosteroid and immunomodulator failure
✓ IL-17/IL-23 inhibitors (Cosentyx, Taltz, Skyrizi, Tremfya, Ilumya, Bimzelx): plaque psoriasis MCPs commonly require phototherapy failure AND one systemic therapy (methotrexate or apremilast) failure; PsA may require one DMARD trial
✓ Dupilumab (Dupixent): atopic dermatitis MCP requires TCS failure at adequate potency; asthma MCP requires documentation of severe uncontrolled asthma with high-dose ICS + LABA optimization
✓ GLP-1s (semaglutide, tirzepatide for obesity): Part D MCPs require BMI ≥30 or ≥27 with comorbidity, documented 6-month behavioral intervention, and absence of contraindications; Humana has been aggressive about requiring lifestyle intervention attestation
✓ JAK inhibitors (upadacitinib, baricitinib, tofacitinib): Humana MCPs for RA indications require prior TNF inhibitor failure in addition to DMARD failure, consistent with FDA label warnings for this drug class
✓ Oncology: Humana generally follows NCCN Categories 1 and 2A; biomarker test results must be attached (PD-L1, EGFR, ALK, HER2, MSI-H, TMB, BRCA as applicable to the regimen)

Required Documentation for Humana PA Submissions

Incomplete documentation is the most common fixable cause of Humana PA denials. Humana MCPs specify required documentation with more granularity than most payers. Consistently required elements:

✓ MCP number and the specific criterion being addressed — stating the MCP number in the submission header signals to the reviewer that the documentation is mapped to the right policy
✓ ICD-10 diagnosis code at maximum specificity — Humana's MCPs list the covered ICD-10 codes for each indication; submitting a non-covered code (even if clinically accurate) generates an automatic non-coverage determination
✓ Baseline disease activity score: DAS28 or CDAI for RA; PASI and BSA for psoriasis; Harvey-Bradshaw Index or Mayo score for IBD; DLQI for atopic dermatitis; FEV1 and ACQ for asthma
✓ Prior therapy documentation: each prior agent with drug name, dose, start and stop dates, reason for discontinuation (inadequate response, adverse effect, or contraindication) — Humana reviewers look for specificity here
✓ Specialist involvement: Humana MCPs for most biologics and specialty drugs require the PA to originate from or be co-signed by the relevant specialist (rheumatologist, dermatologist, gastroenterologist, pulmonologist, oncologist)
✓ Lab results: HbA1c for GLP-1 diabetes indications; QuantiFERON/TB testing before biologic initiation; eGFR and LFTs where clinically indicated; biomarker test reports for oncology
✓ Weight and BMI for obesity medication requests — Humana has required a current (within 6 months) BMI documentation from a clinical encounter, not self-reported

Humana Prior Authorization Appeal Process

Humana's appeal process differs meaningfully by line of business. Medicare Advantage appeals follow the mandatory CMS five-level process. Commercial appeals follow a two-level internal structure.

For Humana MA, the appeal pathway is: Level 1 Organization Determination (Humana internal) → Level 2 Independent Review Entity (IRE, currently Maximus Federal Services under CMS contract) → Level 3 ALJ hearing → Level 4 Medicare Appeals Council → Level 5 federal court. Level 2 IRE review is mandatory, independent, and overturns Humana MA denials at a nationally significant rate for well-documented specialty drug cases.

For Humana commercial, the Level 1 internal appeal must be filed within 180 days of the denial for fully insured plans, 60 days for ERISA plans. Humana must respond within 30 days (standard) or 72 hours (urgent). If Level 1 is upheld, a Level 2 external independent review is available.

Peer-to-Peer Review with Humana

Peer-to-peer review is available for most Humana medical benefit PA denials. Request a P2P within 7 calendar days of receiving the denial letter — this is a tighter window than most payers. The number to call is on the denial letter, or use 1-800-523-0023 for MA and 1-888-447-3430 for commercial, and ask for a physician reviewer consultation.

Humana typically schedules P2P calls within 2-4 business days. The reviewing clinician is generally specialty-matched. P2P effectiveness at Humana is highest when the prescriber: (1) pulls the applicable MCP before the call and knows the specific denial criterion by number, (2) has a 2-minute clinical summary ready that addresses that criterion directly, (3) cites the specific guideline or trial that supports the request. P2P calls at Humana that lead with MCP criterion references overturn denials at approximately 55-65% of cases when the clinical case is sound.

Writing an Effective Humana Appeal Letter

The most effective Humana appeal letters are structured around the MCP rather than around the drug or the diagnosis. Reviewers are evaluating whether the patient meets the written criteria — not whether the drug is clinically appropriate in the abstract.

✓ Open with: "This appeal challenges the denial of [drug] dated [date] under Humana Medical Coverage Policy [MCP number], Criterion [X]."
✓ Quote the specific denial criterion from the MCP and then demonstrate, with attached documentation, that the patient meets it
✓ Attach the baseline disease activity score, prior therapy records, and lab values that the MCP requires
✓ Cite the most relevant clinical guideline (ACR for rheumatology, AAD for dermatology, NCCN for oncology, ADA for diabetes) with the specific recommendation number
✓ For step therapy denials: document each required prior therapy with drug name, dose, duration, and outcome — a table format is effective and easy for reviewers to check
✓ For experimental/investigational denials: cite FDA approval status, NCCN category (if oncology), or compendium support (DRUGDEX, AHFS DI for off-label)
✓ Request expedited review if clinical urgency warrants — Humana must respond within 72 hours for expedited appeals
✓ For MA: invoke CMS regulations explicitly — cite 42 CFR 422.566 (coverage determinations) and 42 CFR 422.578 (appeal rights) to signal familiarity with regulatory requirements

High-Volume Humana MCPs to Know

Humana MCPs most frequently encountered in specialty pharmacy workflows:

✓ MCP-DRUG00009 — TNF inhibitors (adalimumab/biosimilars, etanercept, infliximab/biosimilars, certolizumab, golimumab): RA, PsA, AS, Crohn's disease, plaque psoriasis criteria; DMARD failure requirements
✓ MCP-DRUG00018 — IL-17 and IL-23 inhibitors (secukinumab, ixekizumab, guselkumab, risankizumab, bimekizumab): psoriasis, PsA, AS criteria; phototherapy and systemic therapy requirements
✓ MCP-DRUG00031 — Dupilumab (Dupixent): atopic dermatitis, asthma, CRSwNP, EoE; eosinophil thresholds, ICS documentation
✓ MCP-DRUG00045 — GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide, dulaglutide): T2DM and obesity indications; BMI and lifestyle intervention requirements
✓ MCP-DRUG00052 — Checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab, durvalumab): NCCN alignment, biomarker requirements by indication
✓ MCP-DRUG00067 — CGRP inhibitors (erenumab, fremanezumab, galcanezumab, eptinezumab): chronic migraine; prior preventive failure requirements
✓ MCP-DRUG00078 — Multiple sclerosis DMTs (ocrelizumab, ofatumumab, natalizumab, siponimod): diagnosis confirmation, MRI, neurologist requirements
✓ Note: Humana MCP numbers are illustrative — always verify the current MCP number at humana.com as numbering may change with policy updates

Humana Medicare Advantage vs. Commercial: Key Differences

The most important practical difference between Humana MA and commercial PA is the appeal pathway. MA appeals are governed by federal CMS regulations with mandatory timelines and a mandatory independent Level 2 review — Humana cannot deny Level 2 access. Commercial appeals are governed by state law (fully insured) or ERISA (self-funded), with more variable timelines and no mandatory IRE access at Level 2.

For drug coverage specifically, Humana MA Part D plans follow CMS formulary requirements and the Part D coverage determination process. Members have a right to request a coverage determination, exception, or appeal. Humana MA plans cannot impose additional criteria beyond CMS requirements for cancer drug coverage, and must follow NCCN for cancer treatment prior authorization.

Humana commercial plans vary by employer group. Self-funded employers can and do customize the plan design, sometimes with tighter or looser criteria than the standard Humana commercial template. Always verify the specific plan benefit summary for self-funded groups before submitting.